Classic psychedelic medicines for adolescent refractory mental health disease

Adolescent treatment-resistant mental health disorders are increasing worldwide, and standard medications and therapy often fail. Classic psychedelics like psilocybin, LSD-25, and DMT, given within psychedelic-assisted therapy, have shown strong effectiveness in adults with refractory conditions, but adolescents have been excluded from trials. Safety concerns in adolescents are justified but must be weighed against limitations in current evidence, which is observational and underpowered for long-term outcomes. Adult studies indicate low physiological toxicity, minimal dependence risk, and a wide therapeutic index, but these findings cannot be directly applied to developing adolescents. This commentary advocates for cautious, ethically grounded research with these compounds in adolescents who have not responded to other treatments.

Study at a glance

Abstract

Abstract Adolescent refractory mental health disorders are rising globally, contributing to long-term morbidity and substantial societal burden. Conventional psychotropic medications and psychotherapeutic approaches sometimes fail to provide adequate relief, necessitating an interest in novel investigational interventions. Classic psychedelic compounds—Psilocybin, Lysergic Acid Diethylamide (LSD-25), and Dimethyltriptamine (DMT)—administered within Psychedelic Assisted Therapy (PAT) frameworks have shown strong efficacy in adults with refractory psychiatric conditions. However, adolescents remain excluded from clinical trials. Concerns regarding the safety of classic psychedelic use in adolescents are justified and must be contextualized within limitations of existing evidence. Available data are observational and underpowered to detect long-term outcomes. While adult studies suggest low physiological toxicity, minimal dependence liability and a wide therapeutic index, these findings cannot be directly extrapolated to adolescents undergoing neurodevelopment. This commentary advocates for cautious, ethically grounded consideration of controlled research involving classic psychedelic compounds in adolescents with refractory mental health disorders.